Dr. Wang on Precision Medicine in MCL

Michael Wang, MD
Published: Thursday, Jan 16, 2020



Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the move towards precision medicine in mantle cell lymphoma (MCL).

Currently in the MCL space, chemotherapy, targeted therapies, and cellular therapies are being explored to treat patients; however, further research is required to successfully treat patients with MCL, explains Wang.

Wang serves as the co-leader of The University of Texas MD Anderson Center B-Cell Lymphoma Moon Shot program, which examines targeted therapies, cellular therapies, immunotherapies, and epigenetic therapies. This program is moving towards precision medicine, which may combat resistance to chemotherapy, targeted therapy, and cellular therapy. No one therapy alone can cure MCL, concludes Wang.
SELECTED
LANGUAGE


Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the move towards precision medicine in mantle cell lymphoma (MCL).

Currently in the MCL space, chemotherapy, targeted therapies, and cellular therapies are being explored to treat patients; however, further research is required to successfully treat patients with MCL, explains Wang.

Wang serves as the co-leader of The University of Texas MD Anderson Center B-Cell Lymphoma Moon Shot program, which examines targeted therapies, cellular therapies, immunotherapies, and epigenetic therapies. This program is moving towards precision medicine, which may combat resistance to chemotherapy, targeted therapy, and cellular therapy. No one therapy alone can cure MCL, concludes Wang.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x